Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375740 | 0.85 | MAPK14 (0.76) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL2792560 | 0.84 | MAPK14 (0.72) | MAPK14PTPN1RIPK2 | |
| Hydrochloric Acid SCHEMBL28362888 | 0.84 | MAPK14 (0.74) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL3429710 | 0.81 | RIPK2 (0.50) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL28299394 | 0.80 | PTPN1 (0.45) | MAPK14PTPN1RIPK2 | |
| SCHEMBL3374511 | 0.80 | PTPN1 (0.65) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL1335080 | 0.78 | RIPK2 (0.78) | MAPK14PTPN1RIPK2RAB9ASMN1; SMN2 | |
| SCHEMBL4647149 | 0.78 | MAPK14 (0.50) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL4646642 | 0.77 | MAPK14 (0.52) | MAPK14PTPN1RIPK2LMNARAB9A | |
| Hydrochloric Acid SCHEMBL3517693 | 0.77 | RIPK2 (0.76) | MAPK14PTPN1RIPK2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501003-B | Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-2099766-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | Glaxo Group Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008074814-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074814-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | MAPK14 1393/4885PTPN1 3482/4885RIPK2 1523/4885 |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, CYP11B2 | MAPK14 602/4885PTPN1 593/4885RIPK2 711/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | MAPK14 530/4885PTPN1 331/4885RIPK2 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.